Table 2.
Trials of TNF inhibitors in COVID-19.
| Trial (Country) | Design | Intervention | Patient Cohort | Cases/Controls | Status | Trial Number |
|---|---|---|---|---|---|---|
| CATALYST (UK) | Randomised controlled platform study - prospective | Infliximab vs Nalimumab vs Mylotarg vs Standard | Hospitalized | 60 patients per intervention arm 1:1 | Completed Awaiting results | ISRCTN40580903 |
| Tufts (USA) | Uncontrolled single arm study | Infliximab | Hospitalized | 17 cases and 0 controls | Awaiting results | NCT04425538 |
| ACTIV-1 (USA) | Randomised control platform study | Remdesivir + Infliximab vs Remdesivir + Abatacept vs Remdesivir +Cenicriviroc vs Standard | Hospitalized | 2160 patients across 3 interventions and 1 control arm | Recruiting | NCT04593940 |
| AVID-CC (UK) | Randomised controlled study | Adalimumab vs standard | Community | 375 patients per arm 1:1 | Recruiting | ISRCTN33260034 |
| COMBAAT (USA) | Randomised controlled study | Adalimumab vs standard | Community | 1444 patients across 2 arms 1:1 | Pre-recruitment | NCT04705844 |
| Xu (China) | Randomised controlled study | Adalimumab vs standard | Severe or critically ill | 30 patients per arm 1:1 | Suspended | ChiCTR2000030089 |